11.73
price up icon2.23%   0.28
 
loading
前日終値:
$11.45
開ける:
$11.53
24時間の取引高:
129.92K
Relative Volume:
0.23
時価総額:
$483.18M
収益:
$82.71M
当期純損益:
$-102.24M
株価収益率:
-2.5064
EPS:
-4.68
ネットキャッシュフロー:
$-76.57M
1週間 パフォーマンス:
-1.31%
1か月 パフォーマンス:
-6.51%
6か月 パフォーマンス:
-11.79%
1年 パフォーマンス:
-7.62%
1日の値動き範囲:
Value
$11.31
$11.74
1週間の範囲:
Value
$10.62
$11.95
52週間の値動き範囲:
Value
$10.60
$20.70

Urogen Pharma Ltd Stock (URGN) Company Profile

Name
名前
Urogen Pharma Ltd
Name
セクター
Healthcare (1195)
Name
電話
972 9 770 7601
Name
住所
9 HA'TA'ASIYA ST, RA'ANANA
Name
職員
217
Name
Twitter
@UroGenPharma
Name
次回の収益日
2024-11-06
Name
最新のSEC提出書
Name
URGN's Discussions on Twitter

URGN を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
URGN 11.73 483.18M 82.71M -102.24M -76.57M -4.68
VRTX 447.30 115.43B 10.63B -479.80M -1.35B 13.33
REGN 745.59 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 592.15 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 249.57 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 104.51 24.49B 3.30B -501.07M 1.03B 11.54

Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2023-02-08 ダウングレード Jefferies Buy → Hold
2022-04-27 開始されました Berenberg Buy
2020-04-16 繰り返されました H.C. Wainwright Buy
2020-04-13 繰り返されました H.C. Wainwright Buy
2020-01-09 開始されました National Securities Neutral
2019-05-30 開始されました JP Morgan Neutral
2019-05-29 開始されました Goldman Neutral
2019-01-29 開始されました H.C. Wainwright Buy
2018-11-08 再開されました Jefferies Buy
2018-04-04 アップグレード Raymond James Mkt Perform → Outperform
2018-01-02 開始されました Ladenburg Thalmann Buy
2017-11-15 繰り返されました Oppenheimer Outperform
2017-11-15 ダウングレード Raymond James Outperform → Mkt Perform
すべてを表示

Urogen Pharma Ltd (URGN) 最新ニュース

pulisher
Nov 18, 2024

Is UroGen Pharma (NASDAQ:URGN) Weighed On By Its Debt Load? - Simply Wall St

Nov 18, 2024
pulisher
Nov 15, 2024

RA Capital Management, L.P. Increases Stake in UroGen Pharma Ltd - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

Analysis of GREAT POINT PARTNERS LLC's Recent Transaction in Uro - GuruFocus.com

Nov 15, 2024
pulisher
Nov 14, 2024

Analysis of COWEN AND COMPANY, LLC's Strategic Reduction in UroG - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

RTW INVESTMENTS, LP Acquires Significant Stake in UroGen Pharma Ltd - GuruFocus.com

Nov 14, 2024
pulisher
Nov 13, 2024

UroGen Pharma: Choice Based On Near-Term High-Value PDUFA - Seeking Alpha

Nov 13, 2024
pulisher
Nov 13, 2024

UroGen Pharma Reports 2024 Third Quarter Financial Results and Business HighlightsURGN Pharmaceuticals, a leading biotech company focused on urothelial and specialty cancers, disclosed its latest financial outcomes for the third quarter ended Septemb - Defense World

Nov 13, 2024
pulisher
Nov 11, 2024

UroGen Pharma Reports Q3 Results and Drug Progress - TipRanks

Nov 11, 2024
pulisher
Nov 11, 2024

HC Wainwright Forecasts Stronger Earnings for UroGen Pharma - MarketBeat

Nov 11, 2024
pulisher
Nov 09, 2024

UroGen Pharma Ltd. (NASDAQ:URGN) Just Reported, And Analysts Assigned A US$39.93 Price Target - Yahoo Finance

Nov 09, 2024
pulisher
Nov 08, 2024

UroGen Pharma Ltd. (NASDAQ:URGN) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 08, 2024
pulisher
Nov 07, 2024

UroGen Pharma Ltd (URGN) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ... - Yahoo Finance

Nov 07, 2024
pulisher
Nov 06, 2024

Morgan Stanley's Strategic Acquisition of UroGen Pharma Shares - GuruFocus.com

Nov 06, 2024
pulisher
Nov 06, 2024

UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025 - BioSpace

Nov 06, 2024
pulisher
Nov 06, 2024

Urogen Pharma (URGN) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance

Nov 06, 2024
pulisher
Nov 06, 2024

UroGen Pharma Ltd (URGN) Q3 2024 Earnings: EPS of ($0.55) and Re - GuruFocus.com

Nov 06, 2024
pulisher
Nov 06, 2024

UroGen Pharma Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 06, 2024
pulisher
Nov 06, 2024

UroGen Pharma Ltd (URGN) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada

Nov 06, 2024
pulisher
Nov 05, 2024

URGNUroGen Pharma Ltd. Ordinary Shares Latest Stock News & Market Updates - StockTitan

Nov 05, 2024
pulisher
Nov 05, 2024

UroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation Conference - Business Wire

Nov 05, 2024
pulisher
Nov 04, 2024

(URGN) Investment Analysis - Stock Traders Daily

Nov 04, 2024
pulisher
Nov 02, 2024

Rice Hall James & Associates LLC Grows Holdings in UroGen Pharma Ltd. (NASDAQ:URGN) - MarketBeat

Nov 02, 2024
pulisher
Oct 31, 2024

UroGen Pharma (URGN) to Release Quarterly Earnings on Wednesday - MarketBeat

Oct 31, 2024
pulisher
Oct 30, 2024

UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024 - BioSpace

Oct 30, 2024
pulisher
Oct 28, 2024

ENVISION Trial Results Published in the Journal of Urology Report 82.3% Duration of Response 12 Months after Achieving Complete Response for UGN-102, Potentially First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC - Business Wire

Oct 28, 2024
pulisher
Oct 25, 2024

(URGN) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Oct 25, 2024
pulisher
Oct 21, 2024

UroGen started at buy by EF Hutton, RTGel technology cited - MSN

Oct 21, 2024
pulisher
Oct 19, 2024

Investors in UroGen Pharma (NASDAQ:URGN) have unfortunately lost 42% over the last five years - Yahoo Finance

Oct 19, 2024
pulisher
Oct 17, 2024

UroGen Pharma maintains Outperform stock rating on new drug application By Investing.com - Investing.com Australia

Oct 17, 2024
pulisher
Oct 17, 2024

FDA accepts UroGen's NDA for bladder cancer treatment - Investing.com India

Oct 17, 2024
pulisher
Oct 16, 2024

When Would Be The Best Time To Buy UroGen Pharma Ltd (NASDAQ: URGN) Stock? - Stocks Register

Oct 16, 2024
pulisher
Oct 16, 2024

URGN’s Stock Market Pendulum: Swinging Between Gains and Losses - The InvestChronicle

Oct 16, 2024
pulisher
Oct 16, 2024

UroGen Pharma maintains Outperform stock rating on new drug application - Investing.com

Oct 16, 2024
pulisher
Oct 16, 2024

UroGen Pharma Ltd (URGN) looking to reclaim success with recent performance - SETE News

Oct 16, 2024
pulisher
Oct 16, 2024

UroGen Pharma (NASDAQ:URGN) Receives "Outperform" Rating from Oppenheimer - MarketBeat

Oct 16, 2024
pulisher
Oct 16, 2024

Wesbanco Bank Inc. Buys Shares of 74,400 UroGen Pharma Ltd. (NASDAQ:URGN) - MarketBeat

Oct 16, 2024
pulisher
Oct 16, 2024

FDA accepts UroGen’s UGN-102 NDA for bladder cancer treatment - Pharmaceutical Technology

Oct 16, 2024
pulisher
Oct 15, 2024

UroGen Pharma Says FDA Accepts NDA for UGN-102 - Marketscreener.com

Oct 15, 2024
pulisher
Oct 15, 2024

UroGen Announces FDA Acceptance of its New Drug Application for UGN-102 - The Bakersfield Californian

Oct 15, 2024
pulisher
Oct 15, 2024

UroGen Pharma Ltd (URGN) is a good investment, but the stock may be undervalued - US Post News

Oct 15, 2024
pulisher
Oct 15, 2024

UroGen Pharma's (URGN) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat

Oct 15, 2024
pulisher
Oct 15, 2024

UroGen Pharma (NASDAQ:URGN) Upgraded to "Strong-Buy" by EF Hutton Acquisition Co. I - MarketBeat

Oct 15, 2024
pulisher
Oct 14, 2024

EF Hutton initiates UroGen Pharma shares with Buy rating By Investing.com - Investing.com South Africa

Oct 14, 2024
pulisher
Oct 14, 2024

EF Hutton Initiates Coverage of UroGen Pharma (URGN) with Buy Recommendation - MSN

Oct 14, 2024
pulisher
Oct 11, 2024

UroGen Pharma Ltd [URGN] Chief Medical Officer makes an insider sale of 859 shares worth 11,236. - Knox Daily

Oct 11, 2024
pulisher
Oct 10, 2024

Healthy Upside Potential: UroGen Pharma Ltd (URGN) - SETE News

Oct 10, 2024
pulisher
Oct 09, 2024

UroGen Pharma announces executive changes By Investing.com - Investing.com South Africa

Oct 09, 2024
pulisher
Oct 09, 2024

UroGen Pharma Ltd (URGN) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... - Yahoo Finance

Oct 09, 2024
pulisher
Oct 09, 2024

UroGen Pharma Announces Departure of CFO and Appointment of New CFO - MarketBeat

Oct 09, 2024
pulisher
Oct 09, 2024

UroGen Appoints Chris Degnan as Chief Financial Officer - citybiz

Oct 09, 2024
pulisher
Oct 09, 2024

UroGen Pharma announces executive changes - Investing.com

Oct 09, 2024

Urogen Pharma Ltd (URGN) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
大文字化:     |  ボリューム (24 時間):